Leaptx
1 known investors
Leap Therapeutics (Nasdaq: LPTX) develops targeted and immuno-oncology antibody therapeutics for cancer patients, with its lead candidate DKN-01 (sirexatamab), an anti-DKK1 monoclonal antibody, in clinical development for esophagogastric, gynecologic, and colorectal cancers. Its pipeline also includes FL-301, a Claudin18.2-targeting antibody for gastric and pancreatic cancer, and FL-501, a GDF-15-targeting antibody in preclinical development.